(Reuters) - Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion (59 billion pounds), combining two of the world's largest cancer drug businesses in the biggest ...

Bristol-Myers Squibb plans to acquire cancer drugmaker Celgene for $74 billion in cash and stock — one of the largest deals in pharmaceutical history. Together, the company would have nine products ...

(Reuters) - Celgene Corp and Bristol-Myers Squibb Co will have to pay $2.2 billion (£1.74 billion) if either of the drugmakers walks away from their $74 billion (£58.57 billion) merger announced on ...

Drugmaker Bristol-Myers Squibb announced Thursday a $74 billion deal to buy Celgene, in one of the biggest mergers in pharmaceutical industry history. The deal, which still needs the approval of ...

(Reuters) - The U.S. Federal Trade Commission has sought additional information from Bristol-Myers Squibb Co and Celgene Corp and is focusing on the companies' psoriasis treatments as part of its ...

Amid resistance from top shareholders, Bristol-Myers Squibb urged investors in a letter to support its $74 billion deal to acquire cancer drugmaker Celgene, CNBC reports. In the letter, Bristol-Myers ...

A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the drugmaker wronged holders of Celgene contingency value rights by delaying ...